@entity1259 has modest single-agent activity in @entity135 but limited activity in metastatic @entity320 and XXXX : phase II studies by the Eastern Cooperative Oncology Group.

@entity632 @entity135 @entity1 @entity137 @entity1665 @entity390 @entity417 @entity882 @entity5 @entity8253 @entity1259 @entity1398 @entity1370 @entity1431 @entity14 @entity221 @entity320
@entity1259 ( @entity1259 ), a diastereoisomer of @entity632 , has established activity in the treatment of many @entity5 types sensitive to @entity632 . Its activity in other @entity5 targets such as @entity320 , @entity135 , and recurrent @entity14 has been less well defined. Three concurrent phase II studies examined the efficacy and @entity137 of @entity1259 (90 mg/m2 given intravenously at 3-week intervals) in the treatment of 71 @entity1 with the aforementioned @entity5 . Of 66 eligible @entity1 who were assessable for response, one @entity1 (with @entity14 ) achieved a complete response and three @entity1 (with @entity135 ) achieved partial responses. The response rate in @entity1 with @entity135 was 18% (95% confidence interval, 4-43%). Myelosuppression, @entity1665 , and @entity390 were the most frequent @entity137 . Two @entity1 died of @entity1398 and grade IV @entity1431 occurred in six @entity1 (8%). Grade III @entity137 were as follows: @entity1431 (17%), @entity417 (10%), @entity1665 (8%), @entity221 (1%), @entity882 (1%). Grade I or II @entity1370 was noted in four @entity1 at cumulative doses ranging between 375 mg/m2 to 1,283 mg/m2. @entity1259 is ineffective as a single agent at this dose and schedule in the treatment of @entity1 with @entity320 and @entity14 . In @entity135 , a modest response rate encourages further exploration of @entity1259 and related @entity8253 in combination regimens.
